BRIEF published on 05/13/2025 at 07:35, 22 days 2 hours ago Sensorion annonce l'approbation des résolutions de l'assemblée générale des actionnaires Biotechnologie Thérapie Génique Sensorion Résolutions Des Actionnaires Thérapie De La Perte Auditive
BRIEF published on 05/13/2025 at 07:35, 22 days 2 hours ago Sensorion Announces Approval of Shareholders’ Meeting Resolutions Biotechnology Gene Therapy Shareholder Resolutions Sensorion Hearing Loss Therapy
PRESS RELEASE published on 05/13/2025 at 07:30, 22 days 2 hours ago Informations privilégiées / Autres communiqués Sensorion publie les résultats de l’AGM avec adoption de toutes les résolutions recommandées par le CA. Détails des votes disponibles en ligne Biotechnologie Résultats Assemblée Générale Mixte Sensorion Thérapie Auditive
PRESS RELEASE published on 05/13/2025 at 07:30, 22 days 2 hours ago Inside Information / Other news releases Sensorion announces successful adoption of all resolutions at Combined General Meeting. Results available on company's website Biotechnology Resolutions Combined General Meeting Sensorion Hearing Loss
BRIEF published on 05/06/2025 at 07:35, 29 days 2 hours ago Sensorion to Present at ASGCT Annual Meeting Gene Therapy Sensorion Hearing Loss ASGCT Meeting DFNB1A
BRIEF published on 05/06/2025 at 07:35, 29 days 2 hours ago Sensorion présentera à la réunion annuelle de l'ASGCT Thérapie Génique Sensorion Perte Auditive DFNB1A Réunion De L'ASGCT
PRESS RELEASE published on 05/06/2025 at 07:30, 29 days 2 hours ago Informations privilégiées / Autres communiqués Sensorion annonce sa participation à la conférence annuelle de l'ASGCT pour présenter ses avancées en thérapie génique et cellulaire pour la surdité. Détails des posters et programme de développement dévoilés Innovation Thérapie Génique ASGCT Sensorion Perte Auditive
PRESS RELEASE published on 05/06/2025 at 07:30, 29 days 2 hours ago Inside Information / Other news releases Sensorion announces participation at ASGCT Annual Meeting to present gene therapy research for hearing loss. Company focuses on developing innovative therapies. ASGCT 28th meeting details included Research Gene Therapy ASGCT Sensorion Hearing Loss
BRIEF published on 04/25/2025 at 07:35, 1 month 9 days ago Présentation de Sensorion sur la thérapie génique lors de la réunion annuelle de l'ASPO 2025 Essai Clinique Thérapie Génique Perte Auditive SENS-501 Oto-rhino-laryngologie Pédiatrique
BRIEF published on 04/25/2025 at 07:35, 1 month 9 days ago Sensorion's Gene Therapy Presentation at 2025 ASPO Annual Meeting Gene Therapy Clinical Trial Hearing Loss SENS-501 Pediatric Otolaryngology
Published on 06/04/2025 at 01:05, 8 hours 36 minutes ago BEWHERE HOLDINGS INC. (Listed on the TSX Venture Exchange - Stock Symbol “BEW”) Announces Plans to Repurchase Common Shares
Published on 06/03/2025 at 23:00, 10 hours 41 minutes ago NXT Energy Solutions Inc. Announces Results of Annual Meeting of Shareholders
Published on 06/04/2025 at 09:15, 26 minutes ago DN Deutsche Nachhaltigkeit invests in the impact company Save the Water Holding AG / Production of the water-free hand sanitizer SOAPEYA
Published on 06/04/2025 at 09:15, 26 minutes ago XTransfer Marks Strategic Expansion into the Netherlands at Money20/20 Europe
Published on 06/04/2025 at 09:13, 28 minutes ago Axo Copper pulls off first real copper IPO on the TSXV in 2025 with its La Huerta project in Mexico
Published on 06/04/2025 at 08:00, 1 hour 41 minutes ago E-PANGO: Composition du capital au 31 mai 2025
Published on 06/04/2025 at 08:45, 56 minutes ago 2025.06.04 Avis aux porteurs des OCEANEs ISIN FR0013521085
Published on 06/04/2025 at 08:45, 56 minutes ago 2025.06.04 Notice to holders of the Convertible Bond ISIN FR0013521085
Published on 06/04/2025 at 08:02, 1 hour 38 minutes ago Saint-Gobain launches in Finland its lowest carbon glass wool insulation plant in the world
Published on 06/04/2025 at 08:02, 1 hour 38 minutes ago Saint-Gobain lance en Finlande son usine d’isolation la plus bas carbone au monde
Published on 06/04/2025 at 08:00, 1 hour 41 minutes ago Openbaar aanbod tot inschrijving op maximaal 12.121.212 Nieuwe Aandelen in het kader van een kapitaalverhoging in geld met extralegale Voorkeurrechten voor een maximumbedrag van EUR 113.212.120,08 (het
